AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06686472
Drug: TL-925
RxNorm normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TL-925 is an eye drop.
Trial: NCT04984993
Drug: Tadalafil 5mg (Male)
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04984993
Drug: Tadalafil 5mg (Female)
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT06687187
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
Trial: NCT06690541
Drug: Lorlatinib 100 mg
RxNorm normalized name: lorlatinib 100 MG
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients received continuous daily PO dosing of lorlatinib 100mg QD from the date of first dosing (per the current protocol) or until one of the following criteria were met (whichever occurred first): disease progression; initiation of a new anticancer therapy; unacceptable toxicities; global deterioration of health-related symptoms; pregnancy; withdrawal of consent; loss to follow-up; death; investigator decision dictated by protocol non-compliance; or study termination.
Trial: NCT06694740
Drug: Interferon Gamma 1-b
RxNorm normalized name: Interferon gamma 1-b
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
Trial: NCT06691633
Drug: Preoperative Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient receives a one-time preoperative dose of 10 mg of methadone
Trial: NCT06691633
Drug: Preoperative Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patient receives a one-time preoperative dose of 10 mg of oral oxycodone
Trial: NCT06688045
Drug: Nemtabrutinib
RxNorm normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06688045
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01442571
Drug: Saline Injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05301972
Drug: BET Inhibitor
RxNorm normalized name: BET INHIBITOR TEN-010
DrugBank: RO-6870810 (DB15151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromodomain and Extra-Terminal Inhibitor
Trial: NCT05712538
Drug: ARCT-032
RxNorm normalized name: ARCT-810
DrugBank: ARCT-810 (DB17683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
Trial: NCT06694350
Drug: Pembrolizumab+Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
Trial: NCT05592743
Drug: Vorasidenib
RxNorm normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy
Trial: NCT04867798
Drug: Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet
RxNorm normalized name: lamivudine-tenofovir 300 mg-300 mg oral tablet
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PrEP eligible participants will be asked to follow up monthly for 12 months. PrEP will be prescribed for once-daily use and discontinued if HIV tests are positive. At quarterly visits, participants will receive Integrated Next Steps Counseling (iNSC) for PrEP adherence with point-of-care drug level feedback. Participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine tenofovir levels \<1500 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing. Medication refills will consist of 3-month supplies.
Trial: NCT05584137
Drug: HLX26
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Trial: NCT05584137
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody
Trial: NCT06132204
Drug: HRS-7535 Tablets
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-7535 Tablets
Trial: NCT05654181
Drug: PF-07328948
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational drug administered orally
Trial: NCT05535855
Drug: CD19 Directed CAR T Cell
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
Trial: NCT04695925
Drug: Osimertinib 80 MG [Tagrisso]
RxNorm normalized name: osimertinib 80 MG [Tagrisso]
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: osimertinib 80 mg po qd until disease progression
Trial: NCT04695925
Drug: Pemetrexed 500 MG Injection
RxNorm normalized name: pemetrexed 500 MG Injection
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression
Trial: NCT04695925
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin area under curve 5 intravenously every 3 weeks for four cycles
Trial: NCT04995133
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT05833139
Drug: BI 1810631
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1810631
Trial: NCT05833139
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole
Trial: NCT05338320
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia and intrathecal morphine
Trial: NCT06633328
Drug: CD7 CAR-T cells injection
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD7 CAR T cells treat patients with severe aplastic anemia
Trial: NCT06160778
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
Trial: NCT06160778
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
Trial: NCT03841474
Drug: Psychiatric treatment with sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
Trial: NCT03841474
Drug: Psychiatric treatment with escitalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
Trial: NCT04952519
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are treated with high doses of amantadine.
Trial: NCT04874597
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
Trial: NCT05642845
Drug: Atorvastatin film-coated tablet 40 mg
RxNorm normalized name: atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
Trial: NCT06049160
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
Trial: NCT06640647
Drug: HDM1005 injection or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HDM1005 injection or placebo isubcutaneous injection once
Trial: NCT05995600
Drug: Antiplatelet Drug
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel ± other antiplatelet drug
Trial: NCT05995600
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
Trial: NCT06642987
Drug: Vonoprazan Test 20mg
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 1 tablets orally once a day
Trial: NCT06642987
Drug: Vonoprazan Reference 20mg
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 1 tablets orally once a day
Trial: NCT06643208
Drug: TACE-HAIC, Envafolimab and Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
Trial: NCT05746273
Drug: Transdermal Nicotine Patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Trial: NCT05579288
Drug: Nitrous oxide (N2O/O2)
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide (N2O/O2) for pain alleviation
Trial: NCT05579288
Drug: Oxygen (O2)
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen (O2) as placebo for control group
Trial: NCT06468943
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.8mg/kg/21d（d0） Intravenous infusion
Trial: NCT06468943
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160mg bid PO（d0-d20）
Trial: NCT06468943
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375mg/㎡/21d（d0） Intravenous infusion
Trial: NCT06468943
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg PO （d1-d5）/21d
Trial: NCT05032352
Drug: Adjuvant
RxNorm normalized name: RNADJUVANT
DrugBank: Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine (DB16757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
Trial: NCT06117540
Drug: WX390
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: WX390 tablet, 1.1 mg once a day
Trial: NCT04562090
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
Trial: NCT05841771
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation.
Trial: NCT05841771
Drug: Azacitidine or decitabine
RxNorm normalized name: Decitabine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: azacytidine 32mg/m2 or decitabine 5mg/m2
Trial: NCT05570318
Drug: Polyethylene Glycols
RxNorm normalized name: polyethylene glycols
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
Trial: NCT06123468
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
Trial: NCT06136884
Drug: AO-252
RxNorm normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO-252 will be administered oral tablets or capsules daily
Trial: NCT06255340
Drug: BI 3031185
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 3031185
Trial: NCT06491576
Drug: BGT-002
RxNorm normalized name: BGT-DTDS
DrugBank: BGT-DTDS (DB18664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taking the study drug orally
Trial: NCT06085638
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by SC (under the skin) or IV (vein)
Trial: NCT06085638
Drug: Tamibarotene
RxNorm normalized name: Tamibarotene
DrugBank: Tamibarotene (DB04942)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT06085638
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax
Trial: NCT06253611
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 240 mg IV; every 2 weeks
Trial: NCT05404919
Drug: Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-hepatitis B medications
Trial: NCT05212337
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous injection with 60 mg Denosumab once
Trial: NCT05212337
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection with NaCl once
Trial: NCT06438250
Drug: 68Ga-JH04
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose will be 148-222 MBq given intravenously.
Trial: NCT06489652
Drug: 89Zr-Oxine-RY_SW01 Cell Injection
RxNorm normalized name: oxine
DrugBank: Oxyquinoline (DB11145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY_SW01 cells injection
Trial: NCT05411900
Drug: BoNT-A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness.
Trial: NCT06635850
Drug: Mosliciguat
RxNorm normalized name: Mosliciguat
DrugBank: Mosliciguat (DB19425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1, 2, or 3 for inhalation
Trial: NCT06293287
Drug: Subcutaneous enoxaparin sodium
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily
Trial: NCT06496607
Drug: Biological: Solrikitug Low Dose
DrugBank: Solrikitug (DB19301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solrikitug Low Dose subcutaneous injection
Trial: NCT06496607
Drug: Biological: Solrikitug Mid Dose
DrugBank: Solrikitug (DB19301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solrikitug Mid Dose subcutaneous injection
Trial: NCT06496607
Drug: Biological: Solrikitug High Dose
DrugBank: Solrikitug (DB19301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solrikitug High Dose subcutaneous injection
Trial: NCT03733535
Drug: Benralizumab
RxNorm normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
Trial: NCT03733535
Drug: 129 Xenon
RxNorm normalized name: xenon-129
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
Trial: NCT06548763
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4mg/㎡, orally administered, d1-5
Trial: NCT06548763
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg, intravenous drip, d1, q3w
Trial: NCT06549400
Drug: Mexiletine granules for prolonged-release oral suspension
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mexiletine PR
Trial: NCT05533372
Drug: IA-14069
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IA-14069 for oral administration.
Trial: NCT04913090
Drug: XZP-5610 Tablet (for Part A)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily for 1 Day
Trial: NCT04913090
Drug: XZP-5610 Tablet (for Part B)
RxNorm normalized name: Amphotericin B for Injection
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily for 14 Days
Trial: NCT04913090
Drug: XZP-5610 Tablet for Part C2
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered after a high-fat meal orally once daily for 1 Day
Trial: NCT06501352
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Additive to Local anesthetic mixture
Trial: NCT06501352
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Additive to Local anesthetic mixture
Trial: NCT06501352
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT05052385
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per treating physician's decision - non interventional study
Trial: NCT05052385
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As per treating physician's decision - non interventional study
Trial: NCT06407544
Drug: PCA device as rescue medication with IV morphine 1mg if VAS more than 4
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCA device as rescue medication with IV morphine 1mg if VAS more than 4 with a 10 min lock-out time